Screener
Alto Neuroscience ANRO CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Alto Neuroscience’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001999480-26-000012
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Accrued liabilities and other liabilities | (1,753) | (2,701) |
| Net cash used in operating activities | (27,091) | (16,556) |
| Cash Flows from Investing Activities: | ||
| Capital expenditures | (556) | (24) |
| Net cash used in investing activities | (556) | (24) |
| Cash Flows from Financing Activities: | ||
| Proceeds from sale of common stock and pre-funded warrants in 2026 private placement | 120,000 | — |
| Payments from sale of common stock and pre-funded warrants in 2026 private placement | (4,875) | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Alto Neuroscience's capex?
- Alto Neuroscience (ANRO) reported capex of $556K in Q1 2026.
- How has Alto Neuroscience's capex changed year-over-year?
- Alto Neuroscience's capex increased by 2216.7% year-over-year, from $24K to $556K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Alto Neuroscience's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude